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One of the challenges of treating patients with
glomerulonephritis is to accurately assess disease activity. As
renal biopsies are routinely stained for deposits of C3
activation fragments and glomerular C3 deposits are found in
most forms of glomerulonephritis, we sought to determine
whether a relatively noninvasive measure of C3 fragment
deposition in the kidney can serve as a good biomarker of
disease onset and severity. We recently developed a
magnetic resonance imaging (MRI)-based method of
detecting glomerular C3 and used this to track the
progression of renal disease in the MRL/lpr mouse model of
lupus nephritis using superparamagnetic iron oxide
nanoparticles conjugated to complement receptor type 2 as
a targeting agent. Quantitative immunofluorescence showed
that glomerular C3b/iC3b/C3d deposition progressively
increased with disease activity, a finding replicated by the
T2-weighted MRI. The T2 relaxation times decreased with
disease activity in the cortex and medulla of the MRL/lpr but
not in MRL/Mpj control mice. Thus, MRI contrast agents
targeted to glomerular C3 fragments can be used to
noninvasively monitor disease activity in glomerulonephritis.
As therapeutic complement inhibitors are used in patients
with renal disease, this method, should it become feasible in
humans, may identify those likely to benefit from
complement inhibition.
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New biomarkers for the detection and surveillance of glomer-
ulonephritis would be of immense clinical utility.1 The current
standard for diagnosing glomerulonephritis is a percutaneous
renal biopsy. This procedure provides much useful information
about the etiology and activity of the underlying disease.
Biopsies sample only a small proportion of the kidney, however,
and complications occur in approximately 6% of patients.2–4
Less invasive methods of obtaining the information provided by
biopsies would be of great clinical benefit.
The involvement of complement cascade proteins in renal
diseases is well documented. Whether circulating or locally
produced, complement cascade proteins and their proteoly-
tically generated fragments (i.e., fragments of C3 and C4) are
deposited on the glomerulocapillary, mesangial, and tubu-
lointerstitial cells during many types of renal injury.5 Notably,
C3 and C4 fragments are covalently attached to these
sites. Renal biopsies are routinely stained for deposits of
C3 activation fragments (C3b/iC3b/C3d), and glomerular C3
deposits are found in most forms of glomerulonephritis.6
Biopsy series of patients with lupus nephritis have correlated
the presence of C3 fragments with the morphological
classification, although the extent of glomerular C3 fragment
deposition was not rigorously quantified.7
Superparamagnetic iron oxide (SPIO, 60–150 nm in dia-
meter) particles and ultrasmall SPIO (5–40 nm in diameter)
particles can be used as T2-based negative-contrast agents for
magnetic resonance imaging (MRI).8 Furthermore, by con-
jugating SPIO to vectors that bind specific molecules, the SPIO
can be used to detect those molecular targets in vivo. Using this
approach, we have previously developed targeted SPIO and a
T2-mapping MRI protocol to detect intra-renal C3b/iC3b/C3d
deposits in the kidneys of 16-week-old MRL/lpr mice.9 The
targeted SPIO were developed through conjugation with a
chimeric molecule complement receptor type 2 (CR2)-Fc,
generating CR2-targeted SPIO. The molecule comprises the
first two short consensus repeats of human CR2, which has a
specificity to iC3b/C3d complement fragments,10 and mouse
immunoglobulin constant region (Fc).
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In the current study, we sought to determine whether the
abundance of C3b/iC3b/C3d deposition in the kidney can
serve as a good biomarker of disease onset and severity, and
whether their deposition in the kidneys can be monitored
noninvasively using CR2-targeted SPIO and T2-weighted
MRI. To accomplish this, we examined cohorts of MRL/lpr
mice and MRL/Mpj control mice as they aged. We used
quantitative immunofluorescence to correlate C3b/iC3b/C3d
abundance in the glomerular and tubular compartments of
the kidney with the age of the mice. We then tracked the
kidney C3b/iC3b/C3d deposition by T2-weighted MRI:
cohorts of MRL/lpr and control mice, at various ages, were
injected with CR2-targeted SPIO and T2 relaxation times
were calculated from the MRI scans. Reduction in T2
relaxation times, induced by CR2-targeted SPIO, was
correlated with the age of the mice to determine whether it
would reflect C3b/iC3b/C3d deposition in the kidneys.
RESULTS
In MRL/lpr mice, progression of kidney dysfunction is age-
dependent. Proteinuria is absent at 8 weeks of age, but its
incidence increases to 40% by 16 weeks and to 80% by
24 weeks. The MRL/lpr strain exhibits 80% mortality from
renal dysfunction at 24 weeks of age.11 Although the MRL/lpr
model is well characterized, none of the studies, to our
knowledge, document age-dependent glomerular changes in
C3 fragment deposition or whether glomerular C3b/iC3b/
C3d can be used as biomarkers of disease activity. To address
this gap, the kidneys of MRL/lpr mice were studied for C3
fragment deposition (Figure 1a) at different ages, reflective of
age-dependent kidney dysfunction.11 The kidneys of 8-, 16-,
and 22-week-old MRL/lpr mice were immunostained for C3b
and iC3b (collectively referred to as C3b/iC3b hereafter) with
a polyclonal anti-C3 antibody, and for C3d with a polyclonal
anti-C3d antibody. Glomerular C3b/iC3b deposition was
detected at 8 weeks, but progressively increased up to 22 weeks
of age, and positively correlated with age in the MRL/lpr
mice (Figure 1b and c). Glomerular C3d deposition was
also detected at 8 weeks, increased at 16 weeks of age, but
showed a small decrease at 22 weeks (Figure 1b and d). In
addition, the glomeruli of MRL/lpr mouse kidneys displayed
hypercellularity, periglomerular infiltrates of monocytes/
macrophages, increased glomerular surface area, and de-
creased renal function by 22 weeks of age (Supplementary
Figures S1 and S2 online).
Next, we examined the deposition of C3b/iC3b and C3d in
the renal tubulointerstitium of MRL/lpr mice. The staining
pattern for C3b/iC3b/C3d on the tubules of MRL/lpr kidneys
displayed minimal changes with age (Figure 2). A trend
toward reduced C3b/iC3b/C3d deposition with increasing
age was noted on tubules of MRL/lpr kidney cortex, outer
medulla, and inner medulla (Figure 2a and b). At 22 weeks,
the C3b/iC3b levels on the tubules of inner medulla of MRL/
lpr mice showed a small increase relative to the C3b/iC3b
levels at 16 weeks, but the relative fluorescence units
remained low. Overall, these findings demonstrate that
disease progression in MRL/lpr mice is characterized by
increasing C3b/iC3b/C3d deposition in the glomeruli, but
largely unchanged C3b/iC3b/C3d deposition in the tubu-
lointerstitium.
To noninvasively track the deposition of C3b/iC3b/C3d in
the kidneys of MRL/lpr mice, we generated a T2-weighted
MRI contrast agent—CR2-targeted SPIO (as described in the
Materials and Methods section). The CR2-targeted SPIO
particles were tested for binding to C3 fragments in vitro
(Figure 3) and in vivo (Supplementary Figure S3 online). To
confirm that binding of the CR2-targeted SPIO was mediated
by CR2, we pre-injected mice with unlabeled CR2-Fc to block
the C3b/iC3b/C3d binding sites and determined that this
reduced the deposition of CR2-targeted SPIO particles in the
kidney (Supplementary Figure S3 online). The CR2-targeted
SPIO particles were detected in glomeruli and tubules of
injected MRL/lpr mice and did not colocalize with macro-
phages (Supplementary Figure S4 online).
To noninvasively monitor complement C3b/iC3b/C3d
deposition in the MRL/lpr kidneys, the same cohorts of
MRL/lpr (n¼ 7) and MRL/Mpj (control, n¼ 4) mice were
injected with CR2-targeted SPIO at 12, 16, 20, and 24 weeks
of age. MR images of the kidneys were obtained before and
48 h after each SPIO injection. Figure 4 illustrates represen-
tative T2-weighted MR images from 12- and 20-week-old
MRL/lpr and MRL/Mpj mice obtained before and 48 h after
SPIO injection. T2 relaxation times (a quantitative output
of T2-weighted MRI signal) were determined for kidney
cortices, outer medulla, inner medulla, and for muscle. The
method of T2 relaxation time calculation is detailed in the
Materials and Methods section.
A change in T2 relaxation times from pre- to 48 h post-
SPIO injection value (delta T2- (DT2)-relaxation time) was
calculated for muscle and for the left and right kidneys. To
establish whether MRL/lpr and MRL/Mpj kidneys differed
following CR2-targeted SPIO injection, the DT2 relaxation
times for MRL/lpr and MRL/Mpj kidneys and muscle were
plotted against the age of the mice. The results are presented
in Figure 5. Muscle was used as a control tissue, and the DT2
relaxation times of the muscles of MRL/Mpj or MRL/lpr
mice were similar (Figure 5a and Supplementary Table S1
online). The kidney cortex, outer medulla, and inner medulla
of MRL/lpr mice showed significant reductions in DT2
relaxation times at 12, 16, and 20 weeks of age when
compared with those of MRL/Mpj mice (Figure 5b–d for left
kidney only, the right kidney showed similar differences,
Supplementary Table S1 online).
To examine whether the progression of disease in MRL/lpr
mice can be monitored noninvasively using MRI, the
calculated DT2 relaxation times for the tissues of MRL/lpr
mice at different ages were compared with each other. The
data are presented in Figure 5 and Supplementary Table S2
online. Although there was no change in the muscle
DT2 relaxation times with age, a significant reduction in
DT2 relaxation times was observed for cortex, outer medulla,
and inner medulla of MRL/lpr kidneys at 20 weeks when
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compared with earlier ages. This observation is consistent
with the increase in C3b/iC3b deposition with age, in the
kidneys of MRL/lpr mice. In MRL/Mpj mice, DT2 relaxation
times generally did not change with age.
DISCUSSION
The present study was conducted to test two hypotheses: (1)
whether the abundance of glomerular C3b/iC3b/C3d deposi-
tion can serve as a marker of glomerulonephritis disease
progression, and (2) whether CR2-targeted SPIO, directed to
deposited C3 fragments, can track C3b/iC3b/C3d deposition
by quantitative T2-weighted MRI. We demonstrated that as
the MRL/lpr mice aged, their kidneys exhibited an increase in
glomerular C3b/iC3b/C3d deposition. At the latest time
point examined, at 22 weeks of age, the glomerular C3d
deposition decreased slightly relative to that at 16 weeks.
Moreover, CR2-targeted SPIO reduced T2 relaxation times in
the cortex of MRL/lpr mouse kidneys, but not in that of
control mouse kidneys. This reduction was age dependent
(except for the last time point when glomerular C3d also
decreased). Overall, the reduction in the T2 relaxation time
corresponded with C3d deposition in the kidney cortex,
indicating that the CR2-targeted SPIO may be useful
for noninvasive monitoring of complement fragment
deposition within the kidney. Thus, our findings demonstrate
that glomerular C3b/iC3b/C3d deposition is a marker of
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Figure 1 |Glomerular C3b/iC3b/C3d deposition in MRL/lpr mice increases with age. (a) Schematic diagram of conversion of soluble
C3 to C3 fragments. yRegulators of complement activation: CR1—complement receptor type 1; MCP—membrane cofactor protein.
(b) Immunostaining of MRL/lpr kidneys for C3b/iC3b (middle panel) and C3d (bottom panel). No staining is seen when the
anti-C3-fluorescein isothiocyanate (FITC) antibody is omitted (top panel, arrowheads point to glomeruli). (c) Quantification of relative
fluorescence units (RFU) shows an increase in C3b/iC3b deposition in glomeruli of MRL/lpr kidneys with disease progression (from ages 8,
16, and 22 weeks; n¼ 3 mice per age group; RFU for each mouse is a mean RFU obtained from 10 randomly selected glomeruli; horizontal
bars represent the mean RFU from the three mice in the respective age groups; the R2 and P-values for the correlation of RFU with age are
shown and were derived from linear regression analysis). (d) Quantification of RFU shows changes in C3d deposition in glomeruli of MRL/lpr
kidneys with disease progression (from ages 8, 16, and 22 weeks; n¼ 3 mice per age group; RFU for each mouse is a mean RFU obtained
from 10 randomly selected glomeruli; horizontal bars represent the mean RFU from the three mice in the respective age groups). Although
C3d fragment is present in larger C3b/iC3b moieties, the anti-C3d antibody likely did not cross-react with these larger moieties. This is
evident from the discrepancy in the pattern of staining (punctate for C3b/iC3b versus ribbon-like for C3d) and unparalleled changes in
intensity between C3b/iC3b and C3d on the MRL/lpr glomeruli from 16 to 22 weeks. Scale bar in (b) ¼ 200 mm.
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glomerulonephritis activity, and its accumulation in the
kidneys can be noninvasively and repeatedly monitored with
CR2-targeted SPIO and MRI.
Our study also revealed that the relative amounts of C3b/
iC3b and C3d deposition in the glomeruli of aging MRL/lpr
mice diverged at the last time point. The conversion of bound
C3, or more precisely of C3b, to iC3b and then further to
C3d, on human kidney podocytes, is mediated by comple-
ment receptor 1 and factor I. The expression of complement
receptor 1 is reduced in human nephritic kidneys,12 but the
expression of its mouse homolog in MRL/lpr kidneys has not
been studied. It is possible that the expression of the
complement receptor 1 homolog in the MRL/lpr mice
follows the same reduced pattern as that in humans, which
would explain the decreased C3d deposition seen in the
glomeruli of 22-week-old MRL/lpr kidneys.
The magnitude of negative enhancement by CR2-targeted
SPIO seemed to decrease between 20 and 24 weeks. This may
be due to the decrease in conversion of iC3b to C3d in the
older mice. Unfortunately, only a small number of mice
survived up to this age in our study; thus, our analysis of this
time point is less accurate than for the preceding time points.
An unexplained finding of this study was that the CR2-
targeted SPIO reduced T2 relaxation times in the inner
medulla of MRL/lpr kidneys, in spite of the fact that there is
little C3b/iC3b/C3d at this location. This signal reduction
requires CR2 targeting,9 and it is not seen in control mice. It
is possible, therefore, that during intra-renal trafficking of
CR2-targeted SPIO, the CR2 interaction ‘traps’ them within
the diseased kidney. The main route of clearance of SPIO is
the reticuloendothelial system (liver, spleen, lymph nodes,
and bone marrow).13–15 As CR2-targeted SPIO accumulate in
the kidneys of MRL/lpr mice, it is possible that the particles
are phagocytosed and metabolized by local dendritic cells and
macrophages. The surface CR2-Fc protein of the retained
particles may also mediate subsequent uptake via Fc
receptors on nearby macrophages. Finally, it is also possible
that as the retained CR2-targeted SPIO break down within
the kidneys, iron-containing products are metabolized by the
tubular epithelial cells. Thus, our noninvasive method for
tracking disease activity in lupus nephritis will benefit from
optimization of the SPIO vectorization to achieve precise
tissue targeting and greater MRI contrast.
Nevertheless, this technique can be a useful adjunct to
current methods for monitoring glomerulonephritis, such as
percutaneous renal biopsies. This noninvasive method of
detecting C3 fragments in the kidneys can report not only on
inflammatory activity in the kidneys but also on the organ
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Figure 2 | Tubular C3b/iC3b/C3d deposition in MRL/lpr mice reduces with age. (a) Representative images of tubular staining for
C3b/iC3b in cortex (top panel), outer medulla (middle panel) and inner medulla (bottom panel) of MRL/lpr kidneys are presented. Similar
images were obtained for C3d immunostaining (images not shown). Arrowheads point to glomeruli. (b) Changes in tubular C3b/iC3b
or C3d deposition in MRL/lpr mice in relation to age. Quantification of relative fluorescence units (RFU) shows a trend toward a decrease
in tubular C3b/iC3b or C3d staining with disease progression (ages 8, 16, and 22 weeks; n¼ 2 mice for C3d staining of inner medulla of
8-week-old mice and n¼ 3 mice per age group for all other conditions; RFU for each mouse is a mean RFU obtained from 10 randomly
selected tubules from each kidney compartment; horizontal bars represent the mean RFU from all the mice in the respective age
groups). Scale bar in (a) ¼ 200mm.
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Figure 3 |CR2-targeted SPIO particles bind to C3 fragments on opsonized CHO cells. (a) Dotplot diagram of complement receptor
type 2 (CR2)-targeted superparamagnetic iron oxide (SPIO) from flow cytometry analysis with forward scatter (FSC) on the horizontal
axis and side scatter (SSC) on the vertical axis. (b) Flow cytometry profile of the gated SPIO in (a): histogram of untargeted SPIO (filled curve)
is overlaid with histogram from CR2-targeted SPIO (black line). The horizontal axis represents the fluorescence intensity from
biotinylated anti-CR2 antibody 171 and streptavidin-PE (anti-CR2/SA-PE). The histogram shows that CR2-Fc was successfully conjugated to
superparamagnetic iron oxide (SPIO). (c) Dotplot diagram of opsonized Chinese hamster ovary (CHO) cells and CR2-targeted SPIO
from flow cytometry analysis; same axes as in (a). (d) Histogram of unmanipulated CHO cells (filled curve) is overlaid with histogram
from CHO cells opsonized with 10% mouse serum (black line). The deposition of C3b/iC3b on opsonized cells was confirmed with
anti-C3b/iC3b-fluorescein isothiocyanate (FITC)-labeled antibody. (e) Histogram of opsonized CHO cells incubated with CR2-targeted SPIO
and unmanipulated 171 (filled curve) is overlaid with a histogram from opsonized CHO cells incubated with CR2-targeted SPIO and
biotinylated 171. The horizontal axis represents the fluorescence intensity from anti-CR2/streptavidin-PE.
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Figure 4 |MR images of MRL/lpr and MRL/Mpj mice. Representative abdominal magnetic resonance (MR) images at time to
echo (TE) 20ms of 12- and 20-week-old MRL/lpr and MRL/Mpj mice taken before (pre-superparamagnetic iron oxide (SPIO)) and 48 h
following (post-SPIO) complement receptor type 2 (CR2)-targeted SPIO injection. The MR images are colored red for better visual
presentation. A reduction in intensity is observed for left kidney (arrowhead and insert) from pre- to post-SPIO injection for 20-week-old
MRL/lpr mouse. In this same MRL/lpr mouse, the right kidney, although not as dark as the left, is darker than the right kidney of the
same mouse at pre-SPIO injection. It is noteworthy that T2 relaxation times (determined from MR images of kidneys generated from 16
different TE) are a more sensitive measure for detecting SPIO-induced MRI signal reduction than visual evaluations of MR images, all of
which are obtained at a single TE.
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size and contour. Moreover, this method permits the evaluation
of both kidneys in their entirety; thus, it may be less susceptible
to sample error than renal biopsies. Because of the noninvasive
nature of this method, obtaining serial data for an individual
patient may be more feasible than with repeated renal biopsies.
Therefore, the method can be used to estimate the activity of
the underlying disease or monitor the response of a patient to
therapy. Therapeutic complement inhibitors have entered
clinical use for patients with renal disease.16 Monitoring the
state of intra-renal complement activation may be particularly
useful in patients who are candidates for complement inhibitory
therapy. Finally, CR2-targeted SPIO can also be used to detect
deposition of C3 fragments in other tissues.
Untargeted SPIO and ultrasmall SPIO have been used to
detect renal inflammation in numerous animal studies.17–23
More recently, they have been used in several human studies,
including a study to detect macrophage infiltration in
glomerulonephritis and renal allograft rejection in humans.24
In addition, untargeted iron oxide-based contrast agents have
been recently introduced into clinical practice after their
approval from the Food and Drug Administration; they
possess no known toxic side effects. This evidence suggests
that iron oxide-based contrast agents are safe, even in
patients with kidney disease.25
In conclusion, we have found that glomerular C3b/iC3b/
C3d deposition is a marker of glomerulonephritis in MRL/lpr
mice and its accumulation in the kidneys can be noninvasively
and repeatedly monitored with CR2-targeted SPIO and
T2-weighted MRI. This method may be applicable to monitor-
ing progression of lupus nephritis, or its response to therapies,
with several advantages over currently available biomarkers:
this method is noninvasive, it can be applied longitudinally
without the need for repeat renal biopsies, and it reports on
complement activation throughout both kidneys. Overall, this
method may improve our ability to monitor disease activity,
disease progression, and the response to therapy.
MATERIALS AND METHODS
Animals
MRL/lpr and MRL/Mpj mice were purchased from the Jackson
Laboratory (Bar Harbor, ME). The animals were housed under
standard laboratory conditions (a 12-h light/dark cycle, standard
food and water ad libitum). In the present study, two cohorts of
mice were used: one cohort, consisting of seven MRL/lpr and four
MRL/Mpj mice, was followed up from the age of 12 to 24 weeks
with monthly injections of CR2-targeted SPIO and MRI scans.
Another cohort, consisting of nine MRL/lpr mice, was used for
histological analysis. Three mice each were killed at 8, 16, and
22 weeks of age. Tissues and serum were obtained for analysis.
Although we had planned on harvesting the oldest group of mice at
24 weeks of age to match the MRI cohort, the mice appeared ill and
were killed early for humane reasons. All animal procedures were
approved by the University of Colorado Denver animal care and use
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Figure 5 |Noninvasive detection of glomerulonephritis progression. T2 relaxation times were measured before complement
receptor type 2 (CR2)-targeted superparamagnetic iron oxide (SPIO) injection and 48 h following injection. Changes in T2 relaxation times
from preinjected values (DT2 relaxation times in milliseconds (ms)) for (a) muscle, (b) left kidney cortex, (c) outer medulla, and (d) inner
medulla of MRL/lpr and control MRL/Mpj mice at 12, 16, 20, and 24 weeks are presented. The right kidneys of MRL/lpr and MRL/Mpj mice
had similar values (data not shown, Supplementary Table S1 online). When DT2 relaxation times were compared between the two strains,
the MRL/lpr mouse kidneys show significantly reduced DT2 relaxation times at 20 weeks for cortex, and 12, 16, and 20 weeks for outer and
inner medullae, from those of age- and area-matched MRL/Mpj mouse kidneys (*Po0.05). When DT2 relaxation times were compared
between the ages within the same strain, the MRL/lpr mouse kidneys showed a significant decrease in DT2 relaxation time at 20 weeks for
cortex and outer medulla, and at 16 weeks for inner medulla (#Po0.05) when compared with earlier ages.
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committee. The animal care before and during the experimental
procedures was conducted in accordance with the policies of National
Institute of Health Guide for the Care and Use of Laboratory Animals.
Immunostaining
To assess whether the abundance of glomerular C3 fragment deposits
increases in an age-dependent manner, the kidneys of MRL/lpr mice at
8, 16, and 22 weeks were examined by immunofluorescence micro-
scopy for C3b/iC3b and C3d. The kidneys were harvested, snap-frozen,
and stored at 80 1C until use. Kidney sections (7mm) of MRL/lpr
mice were fixed with acetone for 1 minute (min) and then rehydrated
with phosphate-buffered saline. The sections were blocked in 10%
normal goat serum (Jackson ImmunoResearch, West Grove, PA) for
1 h at room temperature and then incubated with primary antibodies
(polyclonal goat anti-C3-fluorescein isothiocyanate (FITC)-conjugated
antibody (MP Biomedicals, Solon, OH), which does not recognize C3d
fragment by western blot analysis, polyclonal rabbit anti-human C3d
(Dako (Carpinteria, CA), which may also recognize C3dg), rat anti-
mouse F4/80 (Invitrogen, Carlsbad, CA), and rat anti-mouse CD11b-
phycoerythrin (PE)-conjugated antibody (Invitrogen)) for 1 h, at room
temperature. After five washes with phosphate-buffered saline, 5 min
each, the sections were mounted directly in VectaShield (Vector
Laboratories, Burlingame, CA) or incubated with secondary antibodies
(anti-rabbit-IgG-FITC (Jackson ImmunoResearch, and anti-rat-IgG-
Alexa-594 (Invitrogen)) for 1 h at room temperature, washed again,
and then mounted. The images were acquired under  40 and 10
objectives with an Olympus BX51 microscope (Center Valley, PA) and
a digital camera (Pixera, Santa Clara, CA). To quantify relative
fluorescence units, regions of interest were drawn around glomeruli, or
tubules, and mean fluorescence values obtained with the ‘Measure’
plugin of ImageJ software (NIH, Bethesda, MD). Relative fluorescence
units were measured from 10 glomeruli, or 10 tubules from each kidney
compartment, per mouse per age group.
Synthesis of SPIO, conjugation with CR2-Fc, and test
for C3 binding
The SPIO particles were synthesized and functionalized for conjuga-
tion to proteins as described previously.26,27 The SPIO particles were
conjugated with CR2-Fc as described previously.9 The presence of
CR2-Fc on the surface of conjugated SPIO was confirmed using
fluorescence-activated cell sorting analysis with a biotinylated anti-
CR2 antibody 171 (ref. 28) and streptavidin-PE. The functionality of
the bound CR2-Fc molecules on the surface of CR2-targeted SPIO
was confirmed in a binding assay with opsonized Chinese hamster
ovary cells. First, the Chinese hamster ovary cells at 106 cells/tube
were incubated with 200ml of 10% normal mouse serum in
phosphate-buffered saline at 37 1C to induce opsonization with C3
fragments. The presence of C3 fragments on the surface of Chinese
hamster ovary cells was checked with fluorescence-activated cell
sorting analysis and a directly labeled goat polyclonal anti-C3-FITC
antibody (MP Biomedicals). The opsonized Chinese hamster ovary
cells, at 106 cells/tube, were incubated with 20ml of CR2-targeted
SPIO. The antibody 171, used biotinylated or unmanipulated, was
added to the cell/SPIO mixture. After 1 h incubation, streptavidin-PE
was added to all tubes, and following another 1 h incubation the cell/
SPIO/antibody/streptavidin-PE mixture was washed with phosphate-
buffered saline and examined by fluorescence-activated cell sorting
analysis. All flow cytometry analyses were performed with the
FACSCalibur (BD Biosciences, San Jose, CA) and CellQuest Pro
software (BD Biosciences).
T2-weighted MRI mapping for calculations of T2
relaxation times
Twelve-week-old MRL/lpr mice (lupus group, n¼ 7) and MRL/Mpj
control animals (n¼ 4) were assessed by T2-weighted MRI at
baseline and 48 h after CR2-targeted SPIO injection (0.4 mg or
10–16 mg/kg). The MRI scans were repeated serially at 16, 20, and 24
weeks of age. As expected from the incidence of mortality of 40% for
the 16-week-old and 80% for the 24-week-old MRL/lpr mice,11 only
two mice (out of seven) reached the age of 24 weeks. The mortality
was unlikely to have been caused or accelerated with the injection of
CR2-targeted SPIO, as the incidence of mortality matched that
reported in literature, and all four mice in the control MRL/Mpj
cohort completed the study.
Anesthetized animals were inserted into a 4.7 Tesla Bruker
PharmaScan MRI scanner (Billerica, MA). A Bruker volume coil
(32 mm diameter), tuned into the 1H frequency of 200 MHz, was
used for radiofrequency transmission and reception. An initial fast
spin echo rapid acquisition with relaxation enhancement tri-pilot
imaging, and then a high spatial resolution rapid acquisition with
relaxation enhancement proton density mapping, was conducted.
Thereafter, a series of multi-slice multi-echo T2-weighted pulses
with 16 various echo times was applied for precise T2 mapping and
calculation of T2 relaxation times. The scan parameters were as
follows: field of view¼ 4.00 cm; slice thickness¼ 1.50 mm; inter-slice
distance¼ 1.80 mm; repetition time TR¼ 2650 ms; time to echo
(TE)1¼ 10 ms; TE2¼ 20 ms (followed by 30, 40, 50, 60, 70, 80, 90,
100, 110, 120, 130, 140, 150, 160 ms); slice orientation axial; number
of slices¼ 16; number of averages¼ 2; matrix size¼ 128 256; and
total acquisition time¼ 11 min. The T2 relaxation times (in ms) of
kidney cortex, inner and outer medulla, as well as muscle (as a
control tissue), were calculated using the Bruker ParaVision
software. The Bruker t2vtr-fitting function, based on the equations
below, was applied to calculate T2 times:
S ¼ M0ð1  eTR=T1ÞeTE=T2 ð1Þ
S ¼ C2eTE=T2 ð2Þ
where S is signal intensity, M0 is magnetization, TR is time to repeat,
T1 is spin–lattice relaxation time, TE is time to echo, T2 is spin–spin
relaxation time, and C2 is a constant (¼M0(1eTR/T1)). A visual
representation of the changes in S with increasing TE is presented in
Supplementary Figure S5 online. Delta T2 relaxation times (DT2
relaxation times) were calculated by subtracting the higher T2
relaxation time values at the baseline from the lower T2 relaxation
time values at 48 h after SPIO injection for the same tissue of the
same animal. This resulted in negative DT2 relaxation time values as
the bound SPIO reduced/shortened the T2 relaxation time.
The multi-slice multi-echo T2-weighted MRI protocol used in
our study was chosen for its insensitivity to local field inhomogene-
ities. For this reason, the differences in T2 relaxation times between
the left and right kidneys of the same mouse are unlikely to be due
to local field inhomogeneities, such as the presence of bowel gas.
Therefore, any observed differences in T2 relaxation times between
the left and right kidneys of the same mouse are likely to be due to
natural variability.
Statistical analyses
Unless indicated otherwise, the data are reported as mean±s.e.m.
Correlation of non-longitudinal data of relative fluorescence units
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with age (histological assessment of kidneys from nine MRL/lpr
mice at ages 8, 16, and 22 weeks), all of which were single time-point
measurements for each mouse at each age, was evaluated using
linear regression analysis with the Prism 5.0 software (GraphPad
Software, LA Jolla, CA). Where there were repeated measures on the
same mice (the longitudinal MRI study with seven MRL/lpr and
four MRL/Mpj mice and monthly injections of CR2-targeted SPIO
at 12, 16, 20, and 24 weeks of age), mixed model longitudinal data
analysis with preplanned contrasts was used (to analyze the DT2
relaxation times between MRL/lpr and MRL/Mpj (control) mice,
and the effect of the age of the mouse on DT2 relaxation times) with
the SAS 9.2 statistical software (Cary, NC). P-value of less than 0.05
was considered significant.
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